Tremfya FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved July 13, 2017)
Brand name: Tremfya
Generic name: guselkumab
Dosage form: Injection
Company: Janssen Biotech, Inc.
Treatment for: Plaque Psoriasis, Psoriatic Arthritis
Tremfya (guselkumab) is an interleukin-23 blocker indicated for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis in adults.
Development timeline for Tremfya
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.